A phase 1B multiple ascending dose study of the safety, tolerability, pharmacokinetics, and pharmacodynamics of a medium chain triglyceride supplement in Alzheimer’s disease: Brain energy rescue interventions to treat or delay Alzheimer's disease

Haakon B. Nygaard,Brianne A. Kent,Sam Stager,Penelope J. Slack,Mari L. DeMarco,Christian-Alexandre Castellano,Alexander Rauscher,Stephen C. Cunnane,Howard Feldman

A phase 1B multiple ascending dose study of the safety, tolerability, pharmacokinetics, and pharmacodynamics of a medium chain triglyceride supplement in Alzheimer’s disease: Brain energy rescue interventions to treat or delay Alzheimer's disease

2020

Haakon B. Nygaard
Brianne A. Kent
Sam Stager
Penelope J. Slack
Mari L. DeMarco
Christian-Alexandre Castellano
Alexander Rauscher
Stephen C. Cunnane
Howard Feldman

Author(s): Nygaard, Haakon B; Kent, Brianne A; Stager, Sam; Slack, Penelope; DeMarco, Mari L; Castellano, Christian‐Alexandre; Rauscher, Alexander; Cunnane, Stephen; Feldman, Howard H

Keywords:

safety tolerability
Pharmacology
Medium-chain triglyceride
Psychological intervention
Disease
Medicine
Pharmacokinetics

Correction
Source
Cite
Save
Machine Reading By IdeaReader

References

Citations